Format

Send to

Choose Destination
Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Author information

1
INSERM; UMR 866 , Dijon, France ; Centre Georges François Leclerc , Dijon, France ; Université de Bourgogne , Dijon, France.
2
QIMR Berghofer Medical Research Institute , Herston, Queensland, Australia.
3
Sidney Kimmel Comprehensive Cancer Center; Johns Hopkins University School of Medicine , Baltimore, MD, USA.
4
Institut de Recherches Internationales Servier ; 53, rue Carnot , Suresnes, France.
5
The Shraga Segal Department of Microbiology; Immunology and Genetics ; The Faculty of Health Sciences, Ben Gurion University of the Negev , Beer Sheva, Israel.
6
INSERM, Unité1102; Equipe Labellisée Ligue Contre le Cancer ; Institut de Cancérologie de l'Ouest , Nantes-Saint Herblain; France.
7
Cancer Research Center of Lyon; INSERM UMR 1052 ; CNRS UMR 5286 , Centre Leon Berard, Lyon, France ; Medical Oncology Department , Lyon, France.
8
CRCNA, INSERM U892; CNRS UMR 6299 , Nantes, France ; Institut Mérieux , Lyon, France.
9
University of Pittsburgh Cancer Institute, Departments of Medicine, Surgery, and Immunology , Pittsburgh, PA, USA.
10
INSERM UMR 1116 , Paris, France.
11
Unit of Immunotherapy of Human Tumor; Department of Experimental Oncology and Molecular Medicine ; Fondazione IRCCS Istituto Nazionale dei Tumori , Milan, Italy.
12
Department of Molecular Biotechnology and Health Sciences; Molecular Biotechnology Center, University of Torino , Italy.
13
Cancer Immunology; Inflammation and Tolerance Program; Georgia Regents University Cancer Center ; Augusta, GA, USA.
14
Department of Immunobiology and Yale Cancer Center; Yale University School of Medicine , New Haven, CT, USA.
15
Molecular Immunology Unit; Department of Experimental Oncology and Molecular Medicine ; Fondazione IRCCS Istituto Nazionale dei Tumori ; Milan, Italy.
16
UCLA School of Medicine ; Jonsson Comprehensive Cancer Center Los Angeles , CA, USA.
17
Ludwig Center for Cancer Research; Department of Oncology; University of Lausanne , Switzerland.
18
Department of Medical Oncology and Cancer Vaccine Center; Dana-Farber Cancer Institute and Department of Medicine ; Brigham and Women's Hospital and Harvard Medical School , Boston, MA, USA.
19
The University of Queensland , Queensland, Australia.
20
Cordeliers Research Centre, University of Paris-Descartes , Paris, France.
21
Translational Tumor Immunology; The Wistar Institute , Philadelphia, PA, USA.
22
Department of Microbiology & Immunology; Dodson Interdisciplinary Immunotherapy Institute ; Sylvester Comprehensive Cancer Center; Miller School of Medicine ; University of Miami , Miami, FL, USA.
23
Tisch Cancer Institute; Icahn School of Medicine at Mount Sinai , New York, NY, USA.
24
Department of Medical Oncology; National Center for Tumor Diseases ; Internal Medicine VI; Heidelberg University Hospital , Heidelberg, Germany.
25
Department of Surgery; University of Pittsburgh ; Pittsburgh, PA, USA.
26
Rutgers Cancer Institute of New Jersey , New Brunswick, NJ, USA.
27
Department of Oncology/Pathology; Karolinska Institutet , Stockholm, Sweden.
28
Division of Hematology/Oncology; Department of Medicine ; School of Medicine; University of Pittsburgh , Pittsburgh; PA; USA ; Melanoma and Skin Cancer Program; University of Pittsburgh Cancer Institute , Pittsburgh, PA, USA.
29
National Center for Cancer Care & Research , Doha, Qatar.
30
INSERM-UMR 1043 ; Toulouse, France ; CNRS ; U5282 , Toulouse, France ; Universite de Toulouse; UPS ; Centre de Physiopathologie Toulouse Purpan (CPTP) ; Toulouse, France ; CHU Toulouse Purpan ; Toulouse, France.
31
Hillman Cancer Center; University of Pittsburgh Schools of Health Sciences , Pittsburgh, PA, USA.
32
Unit of Clinical and Experimental Immunology; Humanitas Clinical and Research Center , Rozzano, Italy.
33
Research Branch; Sidra Medical and Research Centre , Doha, Qatar.
34
Division of Oncology; Center for Applied Medical Research and Clinica Universidad de Navarra , Pamploma, Spain.
35
Leiden University; ISA Pharmaceuticals , Netherlands.
36
Center for Immunology and Inflammatory Diseases; Massachusetts General Hospital ; Harvard Medical School , Boston, MA, USA.
37
Deparment of Surgical Oncology; University of Texas MD Anderson Cancer Center , Houston, TX, USA.
38
Departments of Gynecologic Oncology and Immunology; Roswell Park Cancer Institute , Buffalo, NY, USA.
39
Department of Melanoma Medical Oncology; University of Texas MD Anderson Cancer Center , Houston, TX, USA.
40
The Jackson Laboratory for Genomic Medicine , Farmington, CT, USA.
41
Division of Medical Oncology and Immunotherapy; University Hospital , Siena, Italy.
42
Department of Pathology and Immunology; Washington University School of Medicine , St. Louis, MO USA.
43
Department of Dermatology; Universitatsklinikum Erlangen , Erlangen, Germany.
44
Center for Immunotherapy of Cancer and Infectious Diseases; Carole and Ray Neag Comprehensive Cancer Center ; University of Connecticut Health Center , Farmington, CT, USA.
45
Department of Clinical Oncology, INSERM U970; Universite Paris Descartes ; Sorbonne Paris-Cité; Paris ; France; Hôpital Européen Georges Pompidou ; Service d'Immunologie Biologique ; Paris, France.
46
INSERM, Unité1102; Equipe Labellisée Ligue Contre le Cancer ; Institut de Cancérologie de l'Ouest , Nantes-Saint Herblain; France ; Faculty of Medicine, University of Nantes, 44035 Nantes, France.
47
Leiden University Medical Center , Leiden, Netherlands.
48
Ludwig Institute for Cancer Research; BrusselsBranch de Duve Institute ; Université Catholique de Louvain , Brussels, Blegium.
49
Department of Surgery; University of Michigan School of Medicine , Ann Arbor , MI, USA.
50
Department of Pathology; Immunology, and Otolaryngology ; University of Pittsburgh Cancer Institute , Pittsburgh, PA, USA.
51
National Cancer Institute; National Institutes of Health , Bethesda, MD, USA.
52
Evergrande Center for Immunologic Diseases; Ann Romney Center for Neurologic Diseases ; Brigham and Women's Hospital and Harvard Medical School , Boston, MA USA.

Abstract

Whereas preclinical investigations and clinical studies have established that CD8+ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8+ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8+ T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8+ T cell immunity, leading to the emergence of dysfunctional CD8+ T cells. The existence of different types of CD8+ T cells in cancer calls for a more precise definition of the CD8+ T cell immune phenotypes in cancer and the abandonment of the generic terms "pro-tumor" and "antitumor." Based on recent studies investigating the functions of CD8+ T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8+ T cells in cancer.

KEYWORDS:

CD8+ T cells; IFNγ; anergy; anticancer immunity; cytotoxicity; effector; exhaustion; senescence; stemness

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center